Opko Health

Opko Health

Yahoo Finance • 7 hours ago

OPKO Health Inc (OPK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 16% as LabCorp Deal ...

This article first appeared on GuruFocus. Consolidated Revenue: $65.4 million in Q3 2026, up from $56.4 million in Q3 2025. Continuing Operations Revenue Growth: Up 16% year-over-year in Q3 2026. Global Products Segment Revenue: $48.4 mil... Full story

Yahoo Finance • 8 days ago

OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026

OPKO Health, Inc. MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 o... Full story

Yahoo Finance • 21 days ago

Opko Health stock soars on $722M BioReference asset sale

Investing.com -- Opko Health Inc (NASDAQ:OPK) shares surged 20% in premarket trading Thursday after Labcorp Holdings Inc (NYSE:LH) agreed to acquire select assets of BioReference Health for $722 million in cash. Still guessing which stock... Full story

Yahoo Finance • last month

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

OPKO Health, Inc.'s OPK shares have jumped 32.5% year to date, showing impressive momentum. It has significantly outperformed the industry's 6.9% decline and the S&P 500's 11.5% gain. With healthy fundamentals and strong growth opportunit... Full story

Yahoo Finance • 2 months ago

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 dr... Full story

Yahoo Finance • 2 months ago

Top Stock Reports for Meta Platforms, Marvell & Amphenol

Friday, September 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Marvell Technolog... Full story

Yahoo Finance • 2 months ago

Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?

It has been about a month since the last earnings report for Waters (WAT). Shares have added about 3.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is... Full story

Yahoo Finance • 2 months ago

Cocrystal Pharma: The Strategic Reset Investors May Be Missing

By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at... Full story

Yahoo Finance • 2 months ago

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

It has been about a month since the last earnings report for OPKO Health (OPK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release,... Full story

Yahoo Finance • 2 months ago

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health, Inc. OPK is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE's strong performance, strategic partnerships, BioReference restructuri... Full story

Yahoo Finance • 3 months ago

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK)... Full story

Yahoo Finance • 3 months ago

Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28

(RTTNews) - Entera Bio Ltd. (ENTX), a clinical-stage biopharmaceutical company, reported a wider net loss for the second quarter, on surge in financial expense and more than double the growth in research and development expenses. Further,... Full story

Yahoo Finance • 3 months ago

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Cocrystal Pharma, Inc. Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocry... Full story

Yahoo Finance • 3 months ago

Biggest stock movers Tuesday: APLD, CLS, and more

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures showed mixed activity Tuesday morning as investors awaited key technology sector earnings that could shape the outlook for artificial in... Full story

Yahoo Finance • 3 months ago

OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ...

This article first appeared on GuruFocus. Cash Position: Over $300 million in cash, cash equivalents, and restricted cash. Share Repurchase: 9.7 million shares repurchased for approximately $13 million. Diagnostics Revenue: $74.5 million... Full story

Yahoo Finance • 3 months ago

OPKO Health Q2 2026 Earnings Preview

* OPKO Health (OPK [https://seekingalpha.com/symbol/OPK]) is scheduled to announce Q2 earnings results on Monday, July 27th, after market close. * The consensus EPS estimate is -$0.08, [https://seekingalpha.com/symbol/OPK/earnings/esti... Full story

Yahoo Finance • 5 months ago

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class d... Full story

Yahoo Finance • 6 months ago

OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...

This article first appeared on GuruFocus. Revenue: $124.2 million for Q1 2026, down from $149.9 million in Q1 2025. Diagnostics Revenue: $72.2 million in Q1 2026, including $6.5 million from 4K score test. Pharmaceutical Revenue: $52 mill... Full story

Yahoo Finance • 6 months ago

OPKO Health GAAP EPS of -$0.07 in-line, revenue of $124.2M misses by $6.57M

* OPKO Health press release [https://seekingalpha.com/pr/20491381-opko-health-reports-first-quarter-2026-business-highlights-and-financial-results] (OPK [https://seekingalpha.com/symbol/OPK]): Q1 GAAP EPS of -$0.07 in-line. * Revenue o... Full story

Yahoo Finance • 6 months ago

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

OPKO Health, Inc. Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of Hematology (ASH) Annual Meet... Full story